BTIG raised the firm’s price target on Opus Genetics (IRD) to $12 from $7 and keeps a Buy rating on the shares. The investment story seems to have kicked into overdrive with the initial BEST1 correction patient surpassing what the firm had expected, with a highly visually impaired “sentinel patient” experiencing both the structural changes expected and also improved vision, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1
- Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline
- Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%
- Opus Genetics Closes $25 Million Series B Financing
- Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement